SK104493A3 - Phthalazinone derivatives acting anti-arrhythmically and analgetically and eliminating the resistance towards cytostatics - Google Patents

Phthalazinone derivatives acting anti-arrhythmically and analgetically and eliminating the resistance towards cytostatics Download PDF

Info

Publication number
SK104493A3
SK104493A3 SK1044-93A SK104493A SK104493A3 SK 104493 A3 SK104493 A3 SK 104493A3 SK 104493 A SK104493 A SK 104493A SK 104493 A3 SK104493 A3 SK 104493A3
Authority
SK
Slovakia
Prior art keywords
medicament
manufacture
treatment
compound
formula
Prior art date
Application number
SK1044-93A
Other languages
English (en)
Slovak (sk)
Inventor
Jurgen Engel
Bernhard Kutscher
Ilona Fleischhauer
Stefan Szelenyi
Peter Metzenauer
Ulrich Werner
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of SK104493A3 publication Critical patent/SK104493A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
SK1044-93A 1992-10-02 1993-09-30 Phthalazinone derivatives acting anti-arrhythmically and analgetically and eliminating the resistance towards cytostatics SK104493A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4233113 1992-10-02

Publications (1)

Publication Number Publication Date
SK104493A3 true SK104493A3 (en) 1994-08-10

Family

ID=6469448

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1044-93A SK104493A3 (en) 1992-10-02 1993-09-30 Phthalazinone derivatives acting anti-arrhythmically and analgetically and eliminating the resistance towards cytostatics

Country Status (18)

Country Link
US (1) US5556856A (es)
EP (1) EP0590551B1 (es)
JP (1) JP3623975B2 (es)
CN (1) CN1088435A (es)
AT (1) ATE144708T1 (es)
AU (1) AU666773B2 (es)
CA (1) CA2107548A1 (es)
CZ (1) CZ199593A3 (es)
DE (1) DE59304351D1 (es)
DK (1) DK0590551T3 (es)
ES (1) ES2096168T3 (es)
GR (1) GR3022070T3 (es)
HU (1) HUT65353A (es)
MX (1) MX9306120A (es)
RU (1) RU2106143C1 (es)
SK (1) SK104493A3 (es)
UA (1) UA26953C2 (es)
ZA (1) ZA937315B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2005508990A (ja) * 2001-11-07 2005-04-07 ファルマシア・コーポレーション 真核細胞におけるポリアミドの取込みおよび核蓄積を促進する方法
ATE491703T1 (de) 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
MX2008013406A (es) * 2006-04-20 2008-11-04 Glaxo Group Ltd Derivados de 4-bencilftalazinona 2-sustituida como antagonistas de la histamina h1 y h3.
JP2009539962A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
JP2009539963A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤
US20090209520A1 (en) * 2006-06-15 2009-08-20 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
ES2341813T3 (es) * 2006-12-20 2010-06-28 Glaxo Group Limited 4-bencil-1 (2h)-ftalazinonas como antagonistas del receptor h1.
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
ATE525370T1 (de) * 2007-10-11 2011-10-15 Glaxo Group Ltd Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
MX2010004028A (es) 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2011007145A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound as parp inhibitor
US8937178B2 (en) 2013-03-13 2015-01-20 Flatley Discovery Lab Phthalazinone compounds and methods for the treatment of cystic fibrosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3677322D1 (de) * 1985-11-11 1991-03-07 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
JPH0667844B2 (ja) * 1987-03-06 1994-08-31 エーザイ株式会社 虚血性心疾患の治療・予防剤
US5110814A (en) * 1989-01-11 1992-05-05 Asta Pharma Ag Azelastine and its salts used to combat psoriasis

Also Published As

Publication number Publication date
ES2096168T3 (es) 1997-03-01
US5556856A (en) 1996-09-17
AU666773B2 (en) 1996-02-22
JP3623975B2 (ja) 2005-02-23
CA2107548A1 (en) 1994-04-03
UA26953C2 (uk) 1999-12-29
ATE144708T1 (de) 1996-11-15
HU9302784D0 (en) 1993-12-28
AU4876993A (en) 1994-04-14
CZ199593A3 (en) 1994-04-13
HUT65353A (en) 1994-05-02
EP0590551A3 (es) 1994-08-31
EP0590551B1 (de) 1996-10-30
CN1088435A (zh) 1994-06-29
DE59304351D1 (de) 1996-12-05
ZA937315B (en) 1994-04-22
RU2106143C1 (ru) 1998-03-10
EP0590551A2 (de) 1994-04-06
MX9306120A (es) 1994-04-29
DK0590551T3 (da) 1997-04-21
GR3022070T3 (en) 1997-03-31
JPH06312928A (ja) 1994-11-08

Similar Documents

Publication Publication Date Title
SK104493A3 (en) Phthalazinone derivatives acting anti-arrhythmically and analgetically and eliminating the resistance towards cytostatics
White et al. Mitochondria accumulate Ca2+ following intense glutamate stimulation of cultured rat forebrain neurones.
Arnold et al. Effects of atropine, reserpine, 6-hydroxydopamine, and handling on seizure development in the rat
Doi et al. Actions of excitatory amino acid antagonists on synaptic inputs to the rat medial vestibular nucleus: an electrophysiological study in vitro
Frambach et al. Beta adrenergic receptors on cultured human retinal pigment epithelium.
Xu et al. Synaptic potentials evoked in spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation
Mclean et al. The distribution of NADPH-diaphorase-labelled interneurons and the role of nitric oxide in the swimming system of Xenopus laevis larvae
Jordan et al. Effects of early undernutrition on hippocampal development and function
Rosen et al. Enhancement of electrically elicited startle by amygdaloid stimulation
Bowers et al. The influence of the frequency and pattern of sympathetic nerve activity on serotonin N‐acetyltransferase in the rat pineal gland.
Ciesielski et al. Response of the diaphragm muscle to electrical stimulation of the phrenic nerve: a histochemical and ultrastructural study
JP2021507944A (ja) 運動ニューロン疾患を含む神経障害のための組成物および治療方法
Hertzler 5‐Hydroxytryptamine and transmission in sympathetic ganglia
ES2920132T3 (es) Compuesto de ácido tetrámico 4-oxo-alquilado y método de preparación del mismo
Parker et al. Contractile dysfunction of atrial myocardium from endotoxin-shocked guinea pigs
EP4054580A1 (en) Methods of treating depressive disorders
Lorens et al. Lesions in Gudden's tegmental nuclei produce behavioral and 5-HT effects similar to those after raphe lesions
Sargent et al. The influence of normal innervation upon abnormal synaptic connections between frog parasympathetic neurons
Klarskov Non‐cholinergic, non‐adrenergic nerve‐mediated relaxation of pig and human detrusor muscle in vitro
Parks et al. Axon-target cell interactions in the developing auditory system
Heath et al. Frog rod outer segment shedding in vitro: histologic and electrophysiologic observations.
Ruan et al. Effects of nitric oxide on normal and ischemic cochlea of the guinea pig
Briggs Excitatory responses of neurones in rat bulbar reticular formation to bulbar raphe stimulation and to iontophoretically applied 5‐hydroxytryptamine, and their blockade by LSD 25.
CHUJO Neuronal mechanisms of the late N-wave induced in vitro in thin sections of the olfactory cortex of rats
Sabel et al. The saline effect: minimizing the severity of brain damage by reduction of secondary degeneration